$NVDA 250307 110.00P$
So fun

$SUNCON (5263.MY)$ goodbye,U shall be missed

$Tesla (TSLA.US)$ I'm a 5 minute trader

$PHARMA (7081.MY)$
According to Pharmaniaga Berhad (hereinafter referred to as Pharmaniaga) financial report and related announcements for the fourth quarter of 2024, here are some key points of analysis to help determine whether it is worth investing in the company:
1. Financial performance.
Revenue growth: In the fourth quarter of 2024, revenue was 0.926 billion Ringgit, an increase of 17.3% year-on-year. Total revenue for the year was 3.759 billion Ringgit, a year-on-year increase of 10.4%. The revenue growth mainly came from the addition of new products in the franchise Business and price adjustments, as well as increased demand in the Indonesian market.
Profitability: In the fourth quarter of 2024, the pre-tax profit was 13.3 million Ringgit, a significant improvement compared to the loss of 37.4 million Ringgit in the same period of 2023. The total pre-tax profit for the year was 0.194 billion Ringgit, compared to a loss of 78.2 million Ringgit in 2023, indicating a strong recovery.
Earnings per Share (EPS): The basic EPS for the full year of 2024 was 9.15 cents, compared to a loss of 5.86 cents in 2023, showing a significant improvement in the company's profitability.
2. Business Highlights
Franchise Business: Pharmaniaga's franchise agreement with the Ministry of Health of Malaysia is one of its core businesses. In 2024, the company successfully increased the number of products in the franchise product list and conducted...